(Q34414177)

English

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. (English)

1 reference

Europe PubMed Central

2 August 2017

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

8

object named as

E Winer

1 reference

Europe PubMed Central

2 August 2017

author name string

C L Shapiro

1

1 reference

Europe PubMed Central

2 August 2017

S Halabi

2

1 reference

Europe PubMed Central

2 August 2017

V Hars

3

1 reference

Europe PubMed Central

2 August 2017

L Archer

4

1 reference

Europe PubMed Central

2 August 2017

D Weckstein

5

1 reference

Europe PubMed Central

2 August 2017

J Kirshner

6

1 reference

Europe PubMed Central

2 August 2017

W Sikov

7

1 reference

Europe PubMed Central

2 August 2017

H J Burstein

9

1 reference

Europe PubMed Central

2 August 2017

C Hudis

10

1 reference

Europe PubMed Central

2 August 2017

C Isaacs

11

1 reference

Europe PubMed Central

2 August 2017

R Schilsky

12

1 reference

Europe PubMed Central

2 August 2017

E Paskett

13

1 reference

Europe PubMed Central

2 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 February 2011

1 reference

Europe PubMed Central

2 August 2017

European Journal of Cancer

1 reference

Europe PubMed Central

2 August 2017

47

1 reference

Europe PubMed Central

2 August 2017

5

1 reference

Europe PubMed Central

2 August 2017

683-689

1 reference

Europe PubMed Central

2 August 2017

Osteoporosis risk in premenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Cancer treatment and the ovary: the effects of chemotherapy and radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Effect of early menopause on bone mineral density and fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Skeletal complications of breast cancer therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Chemotherapy-induced ovarian failure: manifestations and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Special report on the official positions of the International Society for Clinical Densitometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Management of osteoporosis due to ovarian failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Data monitoring committees and interim monitoring guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

A high incidence of vertebral fracture in women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

The randomization and stratification of patients to clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Age and bone mass as predictors of fracture in a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Allocation of Patients to Treatment in Clinical Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

6 July 2018

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Premenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4211594

27 October 2018

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21324674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21324674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/21324674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Premature ovarian failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/21324674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of natural early menopause on bone mineral density

1 reference

https://pubmed.ncbi.nlm.nih.gov/21324674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.EJCA.2010.11.024

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34414177&oldid=1979238585"